Dexmedetomidine and Kidney Transplantation

Launched by EDUARDO SCHIFFER · Jul 4, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called dexmedetomidine on patients undergoing kidney transplantation (KT). Kidney transplantation is a major surgery for patients with severe kidney failure, but sometimes the new kidney may not function well right after the operation, which is known as delayed graft function (DGF). The researchers want to see if giving dexmedetomidine continuously during the surgery can help improve kidney function after transplantation and reduce the chances of DGF.

To participate in this trial, you need to be an adult (18 years or older) scheduled for kidney transplantation, whether it's planned (elective) or urgent. However, there are some exclusions, like if you have certain heart conditions or have recently had treatment with dexmedetomidine. If you join the study, you'll receive either dexmedetomidine or a placebo (a substance with no active medication) during your surgery, and researchers will closely monitor your kidney function afterward. This trial aims to gather more evidence about how dexmedetomidine can help kidney transplant patients and potentially improve their recovery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Elective and urgent renal transplantation for end-stage renal insufficiency
• Exclusion Criteria:
• • Age \< 18 years old
• • Any known allergy or hypersensitivity to dexmedetomidine or clonidine
• • Preoperative bradycardia with heart rate \<50
• • Second or third-degree atrioventricular block
• • Left ventricular ejection fraction \<30%
• • Preoperative severe systolic dysfunction (LVEF\<30%)
• • Conduction disorders of the Mobitz 2 or Mobitz 3 type in the absence of a pacemaker
• • Exposure to Dexmedetomidine in the past 30 days
• • Recent cerebrovascular pathology (\< 3 month)